As biopharma companies continue to narrow the focus of their drug-development efforts, drug programs that lack strategic fit—yet still hold scientific promise—are being discontinued. In this private session, we will discuss the mechanisms needed to match those programs with new sources of funding or with organizations that have the capital and capabilities to take them forward.